For Research Use Only. Not for Human or Veterinary Use.
Overview
Semaglutide (development code NN9535) is a synthetic analogue of human GLP-1 that acts as a selective, long-acting GLP-1 receptor agonist. It carries two substitutions from native GLP-1 — an Aib residue at position 8 for resistance to the DPP-4 enzyme, and an Arg substitution — plus a C18 fatty-diacid on Lys26 for albumin binding, which extends its half-life to about seven days. It is the most heavily published GLP-1 receptor agonist in the research literature and is studied by both subcutaneous and oral routes.
🧪Chemical Profile
Property
Value
CAS number
910463-68-2
Development code
NN9535
Class
Selective GLP-1 receptor agonist
Backbone
31-amino-acid GLP-1 analogue; Aib at position 8; C18 fatty-diacid at Lys26
Molecular formula
C₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight
4113.58 g/mol
Purity (HPLC)
≥ 98%
Appearance
White to off-white lyophilized powder
Semaglutide at a glance
Class
Selective GLP-1 receptor agonist
Originator
Novo Nordisk
Research status
Most-published GLP-1 agonist
Study route
Subcutaneous (weekly) or oral (daily)
Half-life
≈ 7 days
Key feature
DPP-4-resistant, long-acting GLP-1 analogue
🔬Mechanism of Action
Semaglutide selectively activates the GLP-1 receptor, a class-B GPCR that signals through Gαs to raise cAMP. The Aib substitution blocks the DPP-4 cleavage that rapidly inactivates native GLP-1, and the fatty-diacid chain binds albumin — together these give the long half-life. Beyond glucose handling, GLP-1R signalling is also studied in cardiovascular and central-nervous-system contexts.
Component
Detail
Primary target
GLP-1 receptor (GLP-1R)
Receptor class
Class B G-protein-coupled receptor
G-protein coupling
Gαs → adenylyl cyclase → cAMP
Downstream signalling
PKA, EPAC2, CREB, PI3K/Akt, MAPK/ERK
DPP-4 resistance
Aib at position 8 blocks enzymatic inactivation
Effect
Studied mechanism
Glucose-dependent insulin secretion
GLP-1R activation in pancreatic β-cells
Glucagon suppression
GLP-1R activation in α-cells
Delayed gastric emptying
Vagal GLP-1R signalling
Appetite suppression
GLP-1R in the hypothalamic arcuate nucleus
Cardiovascular / neuro research
GLP-1R in myocardium and CNS (emerging areas)
💊Pharmacology
Parameter
Value
Half-life (t½)
≈ 7 days (~165–168 h)
Time to peak (Tmax)
12–24 h (SC); 1–3 h (oral)
Bioavailability
≈ 89% (SC); ≈ 1% (oral)
Volume of distribution
≈ 0.3 L/kg
Protein binding
≈ 99% (albumin)
Metabolism
Proteolytic degradation (no CYP involvement)
Elimination
Renal (peptide fragments) and fecal
📚Research Evidence
Semaglutide has one of the largest evidence bases of any peptide. Representative studies and trial programs are named below with their research focus; specific numerical outcomes are not restated here as claims.
Preclinical model
Research focus
Reference
Enzyme-stability / design studies
Albumin binding and half-life extension
Lau J, et al. (2015)
Rodent brain mapping
Arcuate-nucleus GLP-1R and appetite
Secher A, et al. (2014)
Diabetic rodent models
Glycemic and body-weight effects
Kapitza C, et al. (2017)
Clinical program
Phase
Research focus
Reference
SUSTAIN program
Phase 3
Glycemic control in type-2-diabetes research
SUSTAIN trials
SUSTAIN-6
Phase 3b
Cardiovascular outcomes
Marso SP, et al. (2016), NEJM
STEP program
Phase 3
Body-weight endpoints in obesity research
Wilding JPH, et al. (2021), NEJM
PIONEER / SELECT
Phase 3
Oral route; cardiovascular outcomes
Semaglutide clinical program
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
Reported direction / finding
Context
Reference
~15% mean body-weight reduction at 2.4 mg
STEP-1 obesity
Wilding JPH et al., NEJM 2021
Reduced major adverse cardiovascular events
SUSTAIN-6 / SELECT
Marso SP et al., NEJM 2016
Appetite suppression via hypothalamic GLP-1R
rodent brain mapping
Secher A et al., 2014
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
⚗️Dosing & Reconstitution Reference
Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.
Parameter
Reference value
Research dosing range (literature)
0.25–2.4 mg, once weekly (SC), in study protocols
Reconstitution solvent
Bacteriostatic water (0.9% benzyl alcohol)
Final concentration
≈ 1–2.5 mg/mL
Storage (lyophilized)
−20°C, protected from light
Storage (reconstituted)
2–8°C, up to ~14 days
Do not use
If the solution is cloudy or contains particulates
🛡️Safety Profile
Published safety observations for the compound, provided as research reference only. This material is not for human or veterinary use.
Pancreatitis, gallbladder disease, retinopathy-related events at low frequency
Cardiovascular
Modest heart-rate increase; reduced events reported in outcome trials
Rodent finding
Thyroid C-cell findings in rodent studies
Status
For research use only; not for human or veterinary application
📐Physicochemical Properties
Property
Value
Physical state
White to off-white lyophilized powder
Solubility (water)
Freely soluble (> 50 mg/mL)
logP (octanol/water)
≈ 4.5–5.0
Isoelectric point (pI)
≈ 4.7
pH (reconstituted)
7.0–8.0
Stability (lyophilized)
≥ 24 months at −20°C
🏭Synthesis & Manufacturing
Semaglutide is made by solid-phase peptide synthesis of the 31-residue analogue, with the C18 fatty-diacid installed on the Lys26 side chain after selective deprotection. It is shorter than the dual/triple agonists but the fatty-acid conjugation and preparative purification are still the defining steps.
Step
Detail
Strategy
Solid-phase peptide synthesis, Fmoc/tBu chemistry
Resin
Rink amide MBHA resin
Coupling
HATU / HBTU with DIPEA
Fatty-acid conjugation
C18 diacid coupled to Lys26 side chain after selective (Mtt) deprotection
Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
Critical quality attributes: correct molecular weight and low deletion-peptide content. Confirm the C18 fatty-diacid on Lys26 and the Aib substitution.
🔎Analytical Methods
Method
Parameter
Typical result
RP-HPLC (C18, UV 214 nm)
Purity
≥ 98%
HPLC retention
C18, 20–60% B over 25 min
Single main peak
ESI-MS (positive mode)
Identity / mass
[M+H]⁺ ≈ 4114 Da (multiply charged +3 to +7)
MALDI-TOF
Mass confirmation
[M+H]⁺ ≈ 4114 Da (multiply charged +3 to +7)
Amino-acid analysis
Composition
Consistent with the stated sequence
LC-MS (extracted ion)
Deletion-peptide impurities
Within specification
Karl Fischer
Water content
< 6%
LAL assay
Endotoxin
Within specification
Ion chromatography
Residual TFA
< 500 ppm
Representative RP-HPLC purity method:
Column: C18, 5 µm, 250 × 4.6 mm
Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
Gradient: 20–60% B over 25 min · Flow rate: 1.0 mL/min · Detection: UV 214 nm
Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 4114 Da (multiply charged +3 to +7)). Confirm the C18 fatty-diacid on Lys26 and the Aib substitution.
📈Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
Condition
Duration
Result
Lyophilized, −20°C, dark
≥ 24 months
No significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark
≥ 12 months
Minimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)
3 months
< 5% degradation
Reconstituted, 2–8°C, dark
7–14 days
Minor degradation
Reconstituted, 25°C
24–48 h
Use promptly
Light exposure (ICH Q1B)
1.2 M lux·h
Generally light-stable
Freeze–thaw (−20°C ⇄ 25°C)
3 cycles
Acceptable — aliquot to avoid repeats
Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
Minimise freeze-thaw cycles; aliquot material used across many sessions.
Key factor: Confirm the C18 fatty-diacid on Lys26 and the Aib substitution.
📖Selected References
Lau J, et al. Discovery of the once-weekly GLP-1 analogue semaglutide. Journal of Medicinal Chemistry, 2015.
Secher A, et al. The arcuate nucleus mediates GLP-1 receptor agonist–induced weight loss. Journal of Clinical Investigation, 2014.
Marso SP, et al. Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6). New England Journal of Medicine, 2016.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). New England Journal of Medicine, 2021.
✅Quality & Supply
HPLC ≥ 98% purity with a Certificate of Analysis per batch
Identity confirmed by LC-MS; endotoxin tested by LAL
Research samples through to bulk, with worldwide delivery